glutathione mutations in sclc patients NRF2 supports non-small cell lung cancer growth independently of CBP/p300-enhanced synthesis | EMBO Reports Frontiers | Absence of Biomarker-Driven

Frontiers Absence of Biomarker Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies Inhibiting the system xC glutathione axis selectively targets cancers with mutant p53 accumulation Nature Communications JCI Suppression of the SLC7A11 glutathione axis causes synthetic lethality in KRAS mutant lung adenocarcinoma The role of ERBB4 mutations in the prognosis of advanced non small cell lung cancer treated with immune checkpoint inhibitors Molecular Medicine Springer Nature Link

SKU: 9434414119 · From cantondelareina.com.ar